Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/07/23
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePRNewsWire • 03/07/23
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business UpdatePRNewsWire • 02/28/23
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood AdvancesPRNewsWire • 02/02/23
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid LeukemiaPRNewsWire • 01/18/23
Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023Seeking Alpha • 12/30/22
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 MutationPRNewsWire • 12/22/22
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic SyndromesPRNewsWire • 12/15/22
Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ PatientsBusiness Wire • 12/13/22
Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting noticeMarket Watch • 12/02/22
Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 MutationPRNewsWire • 12/01/22
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet HaematologyPRNewsWire • 11/10/22
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/22
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/03/22
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 PatientsPRNewsWire • 11/01/22